Hut 8 Corp vs Immunovant Inc. Common Stock — how do they compare? Hut 8 Corp trades at $84.13 (market cap $9.82B), while Immunovant Inc. Common Stock trades at $30.5 (market cap $6.25B). The key difference: Hut 8 Corp is the larger of the two by market cap, and Hut 8 Corp is more actively traded (10,272,678 versus 1,755,411). Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Immunovant Inc. Common Stock for 1 Days on average.
| HUT | IMVT | |
|---|---|---|
Market Cap | $9.82B | $6.25B |
Volume | 10,272,678 | 1,755,411 |
Sector | Financials | Health |
52-Week High | $133.02 | $44.96 |
52-Week Low | $33.76 | $17.03 |
Typical Hold Time | 11 Days | 1 Days |
Enterprise Value | $17.25B | $5.35B |
Signals from Pluang's Aura AI — not financial advice
HUT trades at $84.27, down 5.63% today, with a bearish technical outlook despite oversold RSI readings. The company reported negative earnings in recent quarters, missing expectations, with a net income margin of -188.59% for 2026. Recent positive developments include securing a $1.07 billion credit facility and analyst optimism around AI infrastructure contracts.
While analyst consensus is strongly bullish with a $162.69 price target, significant execution risks persist given negative profitability and cash flow challenges. The stock offers high potential upside if AI infrastructure contracts materialize but carries substantial risk from ongoing losses and competitive pressures in the digital infrastructure space.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →